Gary A. Lyons
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation. Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RIGL: No Recent Company-Specific News Identified. Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.
Transaction History
| TVTX | ▲ Buy | Option Exercise | 5,000 | $87K | 8/18/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 4,100 | $259K | 8/18/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 900 | $57K | 8/18/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 5,000 | $87K | 8/17/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 500 | $32K | 8/17/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,900 | $119K | 8/17/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,600 | $165K | 8/17/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 1,659 | $0 | 5/21/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 8,000 | $131K | 4/14/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 8,000 | $329K | 4/14/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 15,000 | $718K | 12/3/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 15,000 | $2.3M | 12/3/2025 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 1,435 | $0 | 5/22/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/15/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 18,821 | $285K | 10/4/2024 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 40,000 | $419K | 10/4/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 21,179 | $304K | 10/4/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 11,570 | $1.7M | 8/13/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 11,570 | $495K | 8/13/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 930 | $40K | 7/16/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 930 | $140K | 7/16/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 2,100 | $0 | 5/17/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 12,500 | $535K | 5/14/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 12,500 | $1.7M | 5/14/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/8/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 10,000 | $1.3M | 12/22/2023 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 5,000 | $65K | 12/1/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 5,000 | $584K | 12/1/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 5,000 | $575K | 9/12/2023 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 5,000 | $65K | 9/12/2023 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 5,000 | $65K | 9/1/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 5,000 | $550K | 9/1/2023 | View on chart |
| RIGL | ▲ Buy | Grant | 25,000 | $0 | 5/26/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 4,500 | $0 | 5/17/2023 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 15,000 | $191K | 10/31/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 15,000 | $1.7M | 10/31/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 5,000 | $553K | 10/4/2022 | View on chart |
| RIGL | ▲ Buy | Grant | 25,000 | $0 | 5/20/2022 | View on chart |
| TVTX | ▲ Buy | Grant | 3,000 | $0 | 5/11/2022 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 15,000 | $100K | 4/25/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 15,000 | $1.4M | 4/25/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 5,000 | $525K | 10/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data
Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.